Virtual ACC 2020 | COMPASS Sub-Analysis: Diabetes Increases the Benefit of Rivaroxaban Combined with AAS

In patients with stable coronary or peripheral artery disease, diabetes increases the benefit of combining low doses of rivaroxaban and aspirin vs. aspirin alone. 

ACC 2020 Virtual | Sub-análisis del COMPASS: la diabetes aumenta el beneficio del rivaroxaban más AAS

This analysis was pre-specified in the COMPASS protocol and was presented virtually for the ACC 2020 and simultaneously published in Circulation.

Patients with diabetes, showed numerically greater reduction in terms of the absolute end point, combined MACE (cardiovascular death, MI or stroke) and all cause death, while increased bleeding, caused by adding rivaroxaban, was not higher vs. the non-diabetic. 

The COMPASS originally included 27395 patients with stable coronary or peripheral artery disease, or both. It was presented at ESC 2017 and had showed combining 2,5 mg of rivaroxaban twice a day plus 100 mg of aspirin a day, reduced the combined end point of MACE events and mortality while increasing bleeding vs. aspirin alone. 


Read also: COMPASS: A New Place for Rivaroxaban in Chronic Ischemic Heart Disease.


For the present analysis presented at ACC 2020, the focus was on 6922 diabetic patients initially enrolled vs. 11356 non-diabetic. 

Diabetes did not affect end points significantly, but given the higher risk of baseline events, reduction was numerically greater vs the general population. Bleeding events increased equally in diabetic and non-diabetic patients, as opposed to thrombotic events. 

For now, this increase in bleeding and the economic cost of the drug balance the pros and cons of rivaroxaban.

compas-articulo-original

Original Title: The role of combination antiplatelet and anticoagulation therapy in diabetes and cardiovascular disease: insights from the COMPASS trial. 

Reference: Bhatt DL et al. Circulation. 2020; online before print y presentado simultáneamente en el ACC 2020 en forma virtual.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...